Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in restoring protein expression by harnessing the body's potential with RNA medicine. The company utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome, and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Period	Debt/Equity
2019-12-31	0.02
2020-12-31	0.04
2021-12-31	0.10
2022-12-31	0.39
2023-12-31	0.43
2024-12-31	0.19

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STOK	$34.93	+3.40%	0.68M
3
4
5

Stoke Therapeutics Inc. (STOK) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Stoke Therapeutics Inc. Data in Excel

More STOK Financial Data